AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11199955 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine alone (implied control)
Number of subjects: 0
Study 9416884 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 to 40 mg daily
Number of subjects: 4444
Study 8498166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic class-II inlays (Dicor)
Number of subjects: 39
Study 8498166 — intervention group
Group type: COMPARATOR
Intervention: Dental amalgam restorations
Number of subjects: 39
Study 3324615 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac sodium
Number of subjects: 100
Study 3324615 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 31020797 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP therapy
Number of subjects: 100
Study 31020797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IABP therapy)
Number of subjects: 100
Study 28968228 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotape with exercise program
Number of subjects: 30
Study 28968228 — intervention group
Group type: COMPARATOR
Intervention: Exercise program
Number of subjects: 30
Study 26908739 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive study design for Ebola Virus Disease medical countermeasures
Number of subjects: 0
Study 25032903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal stressors
Number of subjects: 50
Study 25032903 — intervention group
Group type: COMPARATOR
Intervention: Non-interpersonal stressors
Number of subjects: 50
Study 21782389 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Number of subjects: 22
Study 21782389 — intervention group
Group type: COMPARATOR
Intervention: Control (no platelet rich plasma)
Number of subjects: 22
Study 21353104 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 30
Study 21353104 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 5 mg/d
Number of subjects: 30
Study 21353104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both groups
Number of subjects: 30
Study 19791551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexicor (0.3 g per day for 3 weeks)
Number of subjects: 60
Study 19791551 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Aspirin Cardio, Trental, Prestarium, Arifon)
Number of subjects: 60
Study 19791551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexicor
Number of subjects: 60
Study 19791551 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 60
Study 15993304 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerolized cadaver skin
Number of subjects: 10
Study 15993304 — intervention group
Group type: COMPARATOR
Intervention: Silversulfadiazine (standard care)
Number of subjects: 10
Study 14636372 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 23
Study 14636372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10397685 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.1 g/d n‐3 FA for 6 months
Number of subjects: 54
Study 10397685 — intervention group
Group type: COMPARATOR
Intervention: Corn oil as placebo
Number of subjects: 54
Study 8603545 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training (Group 2, n = 11)
Number of subjects: 29
Study 8603545 — intervention group
Group type: EXPERIMENTAL
Intervention: No perioperative biofeedback training (Group 1, n = 14)
Number of subjects: 29
Study 8603545 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 29
Study 1960264 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 23
Study 1960264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6963095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 7
Study 6963095 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 7
Study 6963095 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous fine‐needle biopsy
Number of subjects: 7
Study 6963095 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 7
Study 6704277 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml glucose-free 0.5% bupivacaine
Number of subjects: 40
Study 6704277 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml glucose-free 0.5% bupivacaine
Number of subjects: 40
Study 6704277 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml glucose-free 0.5% bupivacaine
Number of subjects: 40
Study 6704277 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml glucose-free 0.5% bupivacaine
Number of subjects: 40
Study 29031513 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cues about upcoming hazards (e.g., 'crosswalk ahead')
Number of subjects: 57
Study 29031513 — intervention group
Group type: COMPARATOR
Intervention: General cue ('take over control')
Number of subjects: 57
Study 29031513 — intervention group
Group type: COMPARATOR
Intervention: No cue (manual driving throughout)
Number of subjects: 57
Study 29031513 — intervention group
Group type: COMPARATOR
Intervention: Cues about the identity of the upcoming hazards
Number of subjects: 57
Study 27543530 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline group (received ultrasound‐guided saline injection in the ilioinguinal and iliohypogastric nerve region before surgery and ropivacaine after surgery)
Number of subjects: 30
Study 27543530 — intervention group
Group type: COMPARATOR
Intervention: Block group (received injections in the opposite order: ropivacaine before surgery and saline after surgery)
Number of subjects: 30
Study 27543530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 23932338 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ADT
Number of subjects: 985
Study 23932338 — intervention group
Group type: COMPARATOR
Intervention: Deferred ADT
Number of subjects: 985
Study 22105837 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (PDT)
Number of subjects: 32
Study 22105837 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode soft laser therapy (DSL)
Number of subjects: 32
Study 22105837 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough deep scaling and root planing (SRP)
Number of subjects: 32
Study 20359670 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 45
Study 20359670 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 45
Study 18387426 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination (1 x 10(10) cfu once daily) for four weeks
Number of subjects: 100
Study 18387426 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination
Number of subjects: 100
Study 18387426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16354821 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1,000 mg q.d. x 3
Number of subjects: 199
Study 16354821 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 600 mg q.d. x 2 then 300 mg on Day 3 followed by primaquine on Days 7 through 20
Number of subjects: 199
Study 12757214 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined albendazole 400 mg and praziquantel 20 mg/kg
Number of subjects: 84
Study 12757214 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 800 mg as a single dose
Number of subjects: 84
Study 12757214 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole 50 mg/kg as a single dose
Number of subjects: 84
Study 10529039 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg)
Number of subjects: 26
Study 10529039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10529039 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 26
Study 9150978 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting temperature at 5 different levels
Number of subjects: 10
Study 1823215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DP) at 4 to 6 micrograms kg‐1 min‐1 for 3 hours
Number of subjects: 30
Study 1823215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (DT) at 4 to 6 micrograms kg‐1 min‐1 for 3 hours
Number of subjects: 30
Study 7018182 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral estrogen (estradiol valerate), 4 mg daily
Number of subjects: 31
Study 7018182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30276939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive activity in a sitting position (CAS) - reading books or newspapers, writing a diary or letters, solving crossword puzzles, playing board games, using a computer, maintaining housekeeping records; frequency of engagement: one or more times/week
Number of subjects: 5300
Study 30276939 — intervention group
Group type: EXPERIMENTAL
Intervention: Variety of CAS (number of engagements in CAS)
Number of subjects: 5300
Study 29982255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 208
Study 29982255 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 208
Study 26803746 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib administration immediately after surgery
Number of subjects: 120
Study 26803746 — intervention group
Group type: COMPARATOR
Intervention: No celecoxib administration (control)
Number of subjects: 120
Study 24981241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with intravenous sedation
Number of subjects: 21
Study 24981241 — intervention group
Group type: COMPARATOR
Intervention: Only local anesthesia
Number of subjects: 21
Study 22502753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary BMNCs injection (n=17, BMNCs group)
Number of subjects: 27
Study 22502753 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n=10, Control group)
Number of subjects: 27
Study 22502753 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 21058485 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz/15 Hz disperse-dense wave (Group B)
Number of subjects: 60
Study 21058485 — intervention group
Group type: COMPARATOR
Intervention: Control group without electric stimulation (Group C)
Number of subjects: 60
Study 21058485 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz/100 Hz disperse-dense wave (Group A)
Number of subjects: 60
Study 17381977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Restriction (FR): 193 (sem 19) ml water/d
Number of subjects: 13
Study 17381977 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Restriction (ER): 1214 (sem 25) kJ/d
Number of subjects: 13
Study 17381977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid and Energy Restriction (F+ER): Combination of FR and ER
Number of subjects: 13
Study 17381977 — intervention group
Group type: COMPARATOR
Intervention: Control: Estimated energy (12,154 (sem 230) kJ/d) and water (3912 (sem 140) ml/d) requirements
Number of subjects: 13
Study 16395953 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT treatment
Number of subjects: 1402
Study 16395953 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 1402
Study 16395953 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant drug treatment
Number of subjects: 1402
Study 11519769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 to 400 mg/d
Number of subjects: 456
Study 11519769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 to 60 mg/d
Number of subjects: 456
Study 11519769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 9292484 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 48
Study 9292484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise
Number of subjects: 48
Study 8192170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/d) + Bezafibrate (400 mg/d)
Number of subjects: 38
Study 8192170 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (40 mg/d) + Cholestyramine
Number of subjects: 38
Study 8192170 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin monotherapy (40 mg/d)
Number of subjects: 38
Study 3130892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA; 500 mg thrice daily for 7 days)
Number of subjects: 8
Study 30845330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-typhoid conjugate vaccine (Vi-TCV) co-administered with yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months.
Number of subjects: 250
Study 30845330 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccinations (YFV and MCV-A).
Number of subjects: 250
Study 28698337 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic model for management of blunt chest wall trauma patients
Number of subjects: 0
Study 28698337 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 0
Study 28698337 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12v2 survey
Number of subjects: 0
Study 28698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Client Services Receipt Inventory
Number of subjects: 0
Study 28698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative feedback from clinician interviews and research nurse focus group
Number of subjects: 0
Study 28698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economics outcomes data
Number of subjects: 0
Study 24867230 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot-SRV (50 mg of clotrimazole once a day)
Number of subjects: 12
Study 24867230 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole troches (5 troches of 10 mg clotrimazole/day)
Number of subjects: 12
Study 23352380 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited health literacy
Number of subjects: 260
Study 21860292 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of copper IUD 1 week after medical abortion
Number of subjects: 156
Study 21860292 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of copper IUD 4-6 weeks after medical abortion
Number of subjects: 156
Study 21860292 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of copper IUD
Number of subjects: 156
Study 21860292 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of copper IUD
Number of subjects: 156
Study 19738036 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (0.8 mg x kg(‐1) x day(‐1))
Number of subjects: 7
Study 19738036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 17873675 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg for 12 weeks
Number of subjects: 276
Study 17873675 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 276
Study 17873675 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg at 6-month follow-up
Number of subjects: 276
Study 17873675 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 6-month follow-up
Number of subjects: 276
Study 17873675 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg at 12 weeks
Number of subjects: 276
Study 17873675 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 12 weeks
Number of subjects: 276
Study 17873675 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 276
Study 17873675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 15738918 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction of three-dimensional dose distributions from two-dimensional treatment plan information
Number of subjects: 8
Study 11176166 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP (15 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 23
Study 11176166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PEEP (5 cm H2O) with inverse I:E ratio (2:1)
Number of subjects: 23
Study 11176166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PEEP (5 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 23
Study 9176441 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II immunoreactivity in ascites from pregnant OHSS (1,669 ± 418 pg/mL)
Number of subjects: 43
Study 9176441 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II immunoreactivity in peritoneal fluid (PF) during early pregnancy
Number of subjects: 43
Study 9176441 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II immunoreactivity in PF after gonadotropin stimulation
Number of subjects: 43
Study 9176441 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II immunoreactivity in control ascites
Number of subjects: 43
Study 8464431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (National Cholesterol Education Program Step 2 diet)
Number of subjects: 111
Study 8464431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg once daily)
Number of subjects: 111
Study 8464431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet + Lovastatin
Number of subjects: 111
Study 8464431 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet + Placebo
Number of subjects: 111
Study 8464431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 111
Study 8464431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 111
Study 3898925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol
Number of subjects: 0
Study 3898925 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 0
Study 31774002 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) combined with oral lactulose solution
Number of subjects: 251
Study 31774002 — intervention group
Group type: COMPARATOR
Intervention: Oral lactulose solution
Number of subjects: 251
Study 29990586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Yintang and HE-7 acupoints for 5 minutes before surgery
Number of subjects: 60
Study 29990586 — intervention group
Group type: COMPARATOR
Intervention: Sham acupoint intervention
Number of subjects: 60
Study 27495097 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training program (cycling 3 times weekly for 35 minutes for 24 weeks)
Number of subjects: 16
Study 27495097 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical training program after 24 weeks)
Number of subjects: 16
Study 24705391 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 57
Study 24705391 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 57
Study 22240839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (200 mg) alone
Number of subjects: 13
Study 22240839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (200 mg) + 1 g magnesium oxide (MgO)
Number of subjects: 13
Study 22240839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (200 mg) + 20 mg omeprazole
Number of subjects: 13
Study 20017166 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose radiotherapy (<74 Gy) with hormonal therapy
Number of subjects: 0
Study 20017166 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated-dose radiotherapy (≥74 Gy) with hormonal therapy
Number of subjects: 0
Study 20017166 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately escalated dose (74 Gy) with hormonal therapy
Number of subjects: 0
Study 20017166 — intervention group
Group type: EXPERIMENTAL
Intervention: High escalated dose (≥78 Gy) with hormonal therapy
Number of subjects: 0
Study 18664024 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH) with crystalloids (saline solution)
Number of subjects: 100
Study 18664024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ANH)
Number of subjects: 100
Study 18664024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ANH and control groups
Number of subjects: 100
Study 16459893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure lists of high-frequency words
Number of subjects: 0
Study 16459893 — intervention group
Group type: COMPARATOR
Intervention: Pure lists of low-frequency words
Number of subjects: 0
Study 16459893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lists composed of one low-frequency and five high-frequency words
Number of subjects: 0
Study 16459893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lists composed of five low-frequency words
Number of subjects: 0
Study 12782566 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 1339
Study 12782566 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 1339
Study 10480765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,800 IU vitamin E/day
Number of subjects: 36
Study 10480765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8707264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering interferon (IFN) dose (3 mu, 2 mU, 1 mU, and 0.5 mU three times a week, then 0.5 mU twice weekly and once weekly)
Number of subjects: 106
Study 8707264 — intervention group
Group type: COMPARATOR
Intervention: Stopping interferon (IFN) treatment
Number of subjects: 106
Study 8707264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering interferon (IFN) dose
Number of subjects: 106
Study 8452178 — intervention group
Group type: EXPERIMENTAL
Intervention: fleroxacin 400 mg for 1 day
Number of subjects: 195
Study 8452178 — intervention group
Group type: EXPERIMENTAL
Intervention: fleroxacin 400 mg daily for 2 days
Number of subjects: 195
Study 8452178 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 195
Study 8452178 — intervention group
Group type: EXPERIMENTAL
Intervention: fleroxacin (both regimens)
Number of subjects: 195
Study 3006449 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 75 mg
Number of subjects: 24
Study 3006449 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 150 mg
Number of subjects: 24
Study 3006449 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril with Hydrochlorothiazide (Htz)
Number of subjects: 24
Study 3006449 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24